BACKGROUND: Capecitabine and bevacizumab have each been shown to inhibit tumor growth. Their combination failed to improve survival in a phase III trial of metastatic breast cancer (MBC), although it should be noted patients had been heavily pretreated with anthracyclines and taxanes. Our aim was to evaluate whether combination treatment would increase tumor growth inhibition and survival in a breast cancer model. MATERIALS AND METHODS: Mice bearing KPL-4 human estrogen receptor-negative breast adenocarcinoma xenografts were given capecitabine orally daily for 14 days at the maximum tolerated dose (MTD) or half MTD, alone or with 5 mg/kg intraperitoneal bevacizumab twice weekly. RESULTS: Tumor growth inhibition (TGI) and increased life span (ILS) were superior in the combination groups versus monotherapy (p < 0.05). TGI and ILS were significantly improved in the high- versus low-dose capecitabine combination (p < 0.05). CONCLUSION: Capecitabine in combination with bevacizumab provides a basis for pursuing the combination for first-line treatment of MBC.
BACKGROUND:Capecitabine and bevacizumab have each been shown to inhibit tumor growth. Their combination failed to improve survival in a phase III trial of metastatic breast cancer (MBC), although it should be noted patients had been heavily pretreated with anthracyclines and taxanes. Our aim was to evaluate whether combination treatment would increase tumor growth inhibition and survival in a breast cancer model. MATERIALS AND METHODS:Mice bearing KPL-4 humanestrogen receptor-negative breast adenocarcinoma xenografts were given capecitabine orally daily for 14 days at the maximum tolerated dose (MTD) or half MTD, alone or with 5 mg/kg intraperitoneal bevacizumab twice weekly. RESULTS:Tumor growth inhibition (TGI) and increased life span (ILS) were superior in the combination groups versus monotherapy (p < 0.05). TGI and ILS were significantly improved in the high- versus low-dose capecitabine combination (p < 0.05). CONCLUSION:Capecitabine in combination with bevacizumab provides a basis for pursuing the combination for first-line treatment of MBC.
Authors: Miguel Martín; Anatoly Makhson; Joseph Gligorov; Mikhail Lichinitser; Ana Lluch; Vladimir Semiglazov; Nana Scotto; Lada Mitchell; Sergei Tjulandin Journal: Oncologist Date: 2012-03-30
Authors: James W Purcell; Jefferson Davis; Mamatha Reddy; Shamra Martin; Kimberly Samayoa; Hung Vo; Karen Thomsen; Peter Bean; Wen Lin Kuo; Safiyyah Ziyad; Jessica Billig; Heidi S Feiler; Joe W Gray; Kenneth W Wood; Sylvaine Cases Journal: Clin Cancer Res Date: 2010-01-12 Impact factor: 12.531
Authors: Adrian G Murphy; Rory Casey; Aoife Maguire; Miriam Tosetto; Clare T Butler; Emer Conroy; Alison L Reynolds; Kieran Sheahan; Diarmuid O'Donoghue; William M Gallagher; David Fennelly; Breandán N Kennedy; Jacintha O'Sullivan Journal: Sci Rep Date: 2016-10-14 Impact factor: 4.379
Authors: Leopoldo Luistro; Wei He; Melissa Smith; Kathryn Packman; Maria Vilenchik; Daisy Carvajal; John Roberts; James Cai; Windy Berkofsky-Fessler; Holly Hilton; Michael Linn; Alexander Flohr; Roland Jakob-Røtne; Helmut Jacobsen; Kelli Glenn; David Heimbrook; John F Boylan Journal: Cancer Res Date: 2009-09-22 Impact factor: 12.701